R
ecognition of the importance of cough in clinical medicine was the impetus for the original evidence-based consensus panel report on "Managing Cough as a Defense Mechanism and as a Symptom," published in 1998, 1 and this updated revision. Compared to the original cough consensus statement, this revision (1) more narrowly focuses the guidelines on the diagnosis and treatment of cough, the symptom, in adult and pediatric populations, and minimizes the discussion of cough as a defense mechanism; (2) improves on the rigor of the evidence-based review and describes the methodology in a separate section; (3) updates and expands, when appropriate, all previous sections; and (4) adds new sections with topics that were not previously covered. These new sections include nonasthmatic eosinophilic bronchitis (NAEB); acute bronchitis; nonbronchiectatic suppurative airway diseases; cough due to aspiration secondary to oral/pharyngeal dysphagia; environmental/occupational causes of cough; tuberculosis (TB) and other infections; cough in the dialysis patient; uncommon causes of cough; unexplained cough, previously referred to as idiopathic cough; an empiric integrative approach to the management of cough; assessing cough severity and efficacy of therapy in clinical research; potential future therapies; and future directions for research.
To mitigate future diagnostic confusion, two new diagnostic terms have been introduced to replace two older terms that may represent misnomers. The committee unanimously recommends that the term upper airway cough syndrome (UACS) be used in preference to postnasal drip syndrome (PNDS) when discussing cough that is associated with upper airway conditions because it is unclear whether the mechanism of cough is postnasal drip, direct irritation, or inflammation of the cough receptors in the upper airway. The committee also recommends using the term unexplained cough rather than idiopathic cough because it is likely that more than one unknown cause of chronic cough will be discovered. The term idiopathic implies that one is dealing with only one disease.
For managing adult patients with cough, the committee recommends an empiric, integrative diagnostic approach, which is presented in the section entitled "An Empiric Integrative Approach to the Management of Cough". 3 Guidelines for managing acute, subacute, and chronic cough are presented in algorithmic form (Fig 1-3) . Guidelines with algorithms for evaluating chronic cough in pediatric patients Ͻ 15 years of age are presented in the section entitled "Guidelines for Evaluating Chronic Cough in Pediatrics" 2, 4 [Fig 4, 5] . For a full discussion on how to use the algorithms, please refer to these sections.
Summary and Recommendations
Recommendations for each section of these guidelines are listed under their respective section titles.
For an in-depth discussion or clarification of each recommendation, readers are encouraged to read the specific section in question in its entirety. 5 • The recommendations were graded, by consensus by the panel, using the American College of Chest Physicians Health and Science Policy Grading System, which is based on the following two components: quality of evidence; and the net benefit of the diagnostic and therapeutic procedure.
Methodology and Grading of the Evidence for the Diagnosis and Management of Cough
• The quality of evidence is rated according to the study design and strength of other methodologies used in the included studies.
• The net benefit of the recommendations is based on the estimated benefit to the specific patient population described in each recommendation and not for an individual patient. Usually, the net benefit is a clinical benefit to the population of patients defined in the first phrase of the recommendation, but, in recommendations for future research or other nonclinical recommendations, it may be a societal benefit.
• Both the quality of evidence and the net benefit components are listed after each recommendation; their interaction defines the strength of the recommendations.
• The recommendations scale is as follows: A, strong; B, moderate; C, weak; D, negative; I, inconclusive (no recommendation possible); E/A, Figure 1 . Acute cough algorithm for the management of patients Ն 15 years of age with cough lasting Ͻ 3 weeks. For diagnosis and treatment recommendations refer to the section indicated in the algorithm. PE ϭ pulmonary embolism; Dx ϭ diagnosis; Rx ϭ treatment; URTI ϭ upper respiratory tract infection; LRTI ϭ lower respiratory tract infection. Section 7 ϭ Irwin 8 ; Section 8 ϭ Pratter 9 ; Section 9 ϭ Pratter 10 ; Section 10 ϭ Pratter 11 ; Section 11 ϭ Dicpinigaitis 12 ; Section 12 ϭ Irwin 13 ; Section 13 ϭ Braman 14 ; Section 14 ϭ Braman 15 ; Section 16 ϭ Rosen 17 ; Section 22 ϭ Irwin et al. 23 strong recommendation based on expert opinion only; E/B, moderate recommendation based on expert opinion only; E/C, weak recommendation based on expert opinion only; and E/D, negative recommendation based on expert opinion only 6 • There is clear evidence that vagal afferent nerves regulate involuntary coughing.
Anatomy and Neurophysiology of the Cough Reflex
• Coughing, like swallowing, belching, urinating, and defecating, is unique because there is higher cortical control of this visceral reflex.
• Cortical control can manifest as cough inhibition or voluntary cough. The implications of this are several-fold: because placebos can have a profound effect on coughing, treatment studies must be placebo-controlled. Because cough can be an affective behavior, psychological issues must be considered as a cause or effect of coughing.
• There is a need to study the roles of consciousness and perception in coughing.
Global Physiology and Pathophysiology of Cough 7
1. In patients with endotracheal tubes, tracheostomy need not be performed to improve cough effectiveness. Level of evidence, expert opinion; net benefit, substantial; grade of recommendation, E/A 2. Individuals with neuromuscular weakness and no concomitant airway obstruction may benefit from mechanical aids to improve cough. Level of evidence, low; net benefit, intermediate; grade of recommendation, C 3. In patients with ineffective cough, the clinician should be aware of and monitor for possible complications, such as pneumonia, atelectasis, and/or respiratory failure. Level of evidence, low; net benefit, substantial; grade of recommendation, B
Complications of Cough 8
1. In patients complaining of cough, evaluate for a variety of complications associated with coughing (eg, cardiovascular, constitutional, GI, genitourinary, musculoskeletal, neurologic, ophthalmologic, psychosocial, and skin complications), which can lead to a decrease in a patient's health-related quality of life. Level of evidence, low; benefit, substantial; grade of recommendation, B
2. Patients with cough should have a thor- ough diagnostic evaluation, according to the guidelines set forth in this document, to mitigate or prevent these complications. Level of evidence, low; net benefit, substantial; grade of recommendation, B
Overview of Common Causes of Chronic Cough 9
1. In patients with chronic cough and a normal chest roentgenogram finding who are nonsmokers and are not receiving therapy with an angiotensin-converting enzyme (ACE) inhibitor, the diagnostic approach should focus on the detection and treatment of UACS (formerly called PNDS), asthma, NAEB, or GERD, alone or in combination. This approach is most likely to result in a high rate of success in achieving cough resolution. Level of evidence, low; benefit, substantial; grade of recommendation, B 2. In all patients with chronic cough, regardless of clinical signs or symptoms, because Figure 4 . Approach to a child Ͻ 15 years of age with chronic cough. There are limitations of the algorithm, which should be read with the accompanying text. Spirometry can usually be reliably performed in children Ͼ 6 years of age and in some children Ͼ 3 years of age if trained pediatric personnel are present. CXR ϭ chest radiograph. 2 1. In patients with chronic cough that is related to upper airway abnormalities, the committee considers the term UACS to be more accurate, and it should therefore be used instead of the term PNDS. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 2. In patients with chronic cough, the diagnosis of UACS-induced cough should be determined by considering a combination of criteria, including symptoms, physical examination findings, radiographic findings, and, ultimately, the response to specific therapy. Because it is a syndrome, no pathognomonic findings exist. Level of evidence, low; benefit, substantial; grade of recommendation, B 3. In patients in whom the cause of the UACS-induced cough is apparent, specific therapy directed at this condition should be instituted. Level of evidence, low; benefit, substantial; grade of recommendation, B 4. For patients with chronic cough, an empiric trial of therapy for UACS should be administered because the improvement or resolution of cough in response to specific treatment is the Figure 5 . Approach to a child Յ 14 years of age with chronic specific cough (ie, cough associated with other features suggestive of an underlying pulmonary and/or systemic abnormality). Children Ͼ 14 years of age should be managed as outlined in adult guidelines but there is no good evidence where the age cutoff should be. TEF ϭ tracheal esophageal fistula. See the legend of Figure 4 for abbreviation not used in the text.
pivotal factor in confirming the diagnosis of UACS as a cause of cough. 1. In patients with chronic cough due to gastroesophageal reflux disease (GERD), the term acid reflux disease, unless it can be definitively shown to apply, should be replaced by the more general term reflux disease so as not to mislead the clinicians into thinking that all patients with cough due to GERD should improve with acid-suppression therapy. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 2. In patients with chronic cough who also complain of typical and frequent GI complaints such as daily heartburn and regurgitation, especially when the findings of chest-imaging studies and/or clinical syndrome are consistent with an aspiration syndrome, the diagnostic evaluation should always include GERD as a possible cause. Level of evidence, low; benefit, substantial; grade of recommendation, B 3. Patients with chronic cough who have GI symptoms that are consistent with GERD or who fit the clinical profile described in Table 1 in Irwin 13 , should be considered to have a high likelihood of having GERD and should be prescribed antireflux treatment even when they have no GI symptoms. Level of evidence, low; benefit, substantial; grade of recommendation, B
4. In patients with chronic cough, it should not be assumed that GERD has been definitively ruled out as a cause of cough simply because there is a history of antireflux surgery. Level of evidence, low; benefit, substantial; grade of recommendation, B
5. In patients with chronic cough, while tests that link GERD with cough suggest a potential cause-effect relationship, a definitive diagnosis of cough due to GERD requires that cough nearly or completely disappear with antireflux treatment. Level of evidence, low; benefit, substantial; grade of recommendation, B 6. In patients with chronic cough being evaluated for GERD, the 24-h esophageal pH-monitoring test is the most sensitive and specific test; however, it is recommended that the test results be interpreted as normal only when conventional indices for acid reflux are within the normal range and no reflux-induced coughs appear during the monitoring study. Level of evidence, low; benefit, substantial; grade of recommendation, B 7. In patients with cough who are undergoing 24-h monitoring, a low percentage of coughs associated with (or induced by) reflux does not exclude a diagnosis of cough due to GERD. Level of evidence, low; benefit, substantial; grade of recommendation, B
8. In patients with cough due to GERD, the degree of abnormality noted in the esophageal pH-monitoring variables, such as the frequency and duration of reflux events, does not directly correlate with the severity of the patients' cough. Level of evidence, low; benefit, substantial; grade of recommendation, B 9. In diagnosing nonacid GERD as the cause of cough, barium esophagography may be the only available test to reveal GER of potential pathologic significance in this setting (see the "Discussion" section regarding esophageal impedance monitoring). When this is the case, barium esophagography is the test of choice to reveal GER of potential pathologic significance. Level of evidence, low; benefit, substantial; grade of recommendation, B 10. In patients with cough due to GERD, a normal esophagoscopy finding does not rule out GERD as the cause of cough. Level of evidence, low; benefit, substantial; grade of recommendation, B 11. For patients fitting the clinical profile for cough due to GERD, it is recommended that treatment be initially started in lieu of testing. Level of evidence, low; benefit, substantial; grade of recommendation, B 12. For patients fitting the clinical profile for cough due to GERD, the performance of 24-h esophageal pH monitoring is recommended on therapy when cough does not improve or resolve to assist in determining whether the therapy needs to be intensified or if medical therapy has failed. Level of evidence, low; benefit, substantial; grade of recommendation, B
13. For patients with chronic cough, the following tests are not routinely recommended to link cough with GERD: (a) assessing for lipidladen macrophages in BAL fluid and induced sputum, because this test has not been studied in patients with chronic cough and because a positive test result is not specific for aspiration; (b) exhaled nitric oxide measurements, because they do not appear to be helpful in diagnosing cough due to GERD; (c) a Bernstein test, because a negative Bernstein test result cannot be used to exclude the diagnosis of cough due to GERD; and (d) inhaled tussigenic challenges with capsaicin, because they are not specific for coughs due to GERD and because the test result can be positive in patients with GERD without cough. Level of evidence, low; benefit, conflicting; grade of recommendation, I
14. In patients who meet the clinical profile predicting that silent GERD is the likely cause of chronic cough or in patients with chronic cough who also have prominent upper GI symptoms consistent with GERD, an empiric trial of medical antireflux therapy is recommended. Level of evidence, low; benefit, substantial; grade of recommendation, B 15. For treating the majority of patients with chronic cough due to GERD, the following medical therapies are recommended: (a) dietary and lifestyle modifications; (b) acid suppression therapy; and (c) the addition of prokinetic therapy either initially or if there is no response to the first two therapies. The re-sponse to these therapies should be assessed within 1 to 3 months. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 16. In patients in which this empiric treatment fails, it cannot be assumed that GERD has been ruled out as a cause of chronic cough; rather, the objective investigation for GERD is then recommended because the empiric therapy may not have been intensive enough or medical therapy may have failed. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 17. In some patients, cough due to GERD will favorably respond to acid suppression therapy alone; proton pump inhibition may be effective when H 2 -antagonism has been ineffective; prokinetic therapy and diet, when added to proton pump inhibition, may be effective when proton pump inhibition alone has been ineffective. Level of evidence, low; benefit, substantial; grade of recommendation, B
18. Patients requiring an intensive medical treatment regimen should be treated with the following: (a) antireflux diet that includes no > 45 g of fat in 24 h and no coffee, tea, soda, chocolate, mints, citrus products, including tomatoes, or alcohol, no smoking, and limiting vigorous exercise that will increase intraabdominal pressure; (b) acid suppression with a proton pump inhibitor; (c) prokinetic therapy; and (d) efforts to mitigate the influences of comorbid diseases such as obstructive sleep apnea or therapy for comorbid conditions (eg, nitrates, progesterone, and calcium channel blockers) whenever possible. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 19. In patients with chronic cough due to GERD that has failed to improve with the most maximal medical therapy, which includes an intensive antireflux diet and lifestyle modification, maximum acid suppression, and prokinetic therapy, and the rest of the spectrum of treatment options in Table 3 1. In a patient with an acute respiratory infection manifested predominantly by cough, with or without sputum production, lasting no more than 3 weeks, a diagnosis of acute bronchitis should not be made unless there is no clinical or radiographic evidence of pneumonia, and the common cold, acute asthma, or an exacerbation of COPD have been ruled out as the cause of cough. Quality of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 2. In patients with the presumed diagnosis of acute bronchitis, viral cultures, serologic assays, and sputum analyses should not be routinely performed because the responsible organism is rarely identified in clinical practice. Quality of evidence, low; benefit, intermediate; grade of recommendation, C 3. In patients with acute cough and sputum production suggestive of acute bronchitis, the absence of the following findings reduces the likelihood of pneumonia sufficiently to eliminate the need for a chest radiograph: (1) heart rate > 100 beats/min; (2) respiratory rate > 24 breaths/min; (3) oral body temperature of > 38°C; and (4) chest examination findings of focal consolidation, egophony, or fremitus. Quality of evidence, low; benefit, substantial; grade of recommendation, B 4a. For patients with the putative diagnosis of acute bronchitis, routine treatment with antibiotics is not justified and should not be offered. Quality of evidence, good; benefit, none; grade of recommendation, D 4b. For these patients, the decision not to use an antibiotic should be addressed individually and explanations should be offered because many patients expect to receive an antibiotic based on previous experiences and public expectation. Quality of evidence, expert opinion; benefit, intermediate; grade of recommendation, E/B 5. Children and adult patients with confirmed and probable whooping cough should receive a macrolide antibiotic and should be isolated for 5 days from the start of treatment; early treatment within the first few weeks will diminish the coughing paroxysms and prevent spread of the disease; the patient is unlikely to respond to treatment beyond this period. Level of evidence, good; net benefit, substantial; grade of evidence, A 6a. In most patients with a diagnosis of acute bronchitis, ␤ 2 -agonist bronchodilators should not be routinely used to alleviate cough. Quality of evidence, fair; benefit, none; grade of recommendation, D 6b. In select adult patients with a diagnosis of acute bronchitis and wheezing accompanying the cough, treatment with ␤ 2 -agonist bronchodilators may be useful. Quality of evidence, fair; benefit, small/weak; grade of recommendation, C 7. In patients with a diagnosis of acute bronchitis, antitussive agents are occasionally useful and can be offered for short-term symptomatic relief of coughing. Quality of evidence, fair; benefit, small/weak; grade of recommendation, C 8. In patients with a diagnosis of acute bronchitis, because there is no consistent favorable effect of mucokinetic agents on cough, they are not recommended. Quality of evidence, fair; benefit, conflicting; grade of recommendation, I
Chronic Cough Due to Chronic Bronchitis 15 1. Adults who have a history of chronic cough and sputum expectoration occurring on most days for at least 3 months and for at least 2 consecutive years should be given a diagnosis of chronic bronchitis when other respiratory or cardiac causes of chronic productive cough are ruled out. Level of evidence, low; net benefit, substantial; grade of recommendation, B 2. The evaluation of patients with chronic cough should include a complete history regarding exposures to respiratory irritants including cigarette, cigar, and pipe smoke; passive smoke exposures; and hazardous environments in the home and workplace. All are predisposing factors of chronic bronchitis. Level of evidence, low; net benefit, substantial; grade of recommendation, B
3. Smoke-free workplace and public place laws should be enacted in all communities. Level of evidence, expert opinion; net benefit, substantial; grade of recommendation, E/A 4. Stable patients with chronic bronchitis who have a sudden deterioration of symptoms with increased cough, sputum production, sputum purulence, and/or shortness of breath, which are often preceded by symptoms of an upper respiratory tract infection, should be considered to have an acute exacerbation of chronic bronchitis, as long as conditions other than acute tracheobronchitis are ruled out or are considered unlikely. Level of evidence, expert opinion; net benefit, substantial; grade of recommendation, E/A 5. In patients with chronic cough who have chronic exposure to respiratory irritants, such as personal tobacco use, passive smoke exposure, and workplace hazards, avoidance should always be recommended. It is the most effective means to improve or eliminate the cough of chronic bronchitis. Ninety percent of patients will have resolution of their cough after smoking cessation. Level of evidence, good; net benefit, substantial; grade of recommendation, A 6. In stable patients with chronic bronchitis, there is no role for long-term prophylactic therapy with antibiotics. Level of evidence, low; benefit, none; grade of recommendation, I
7. In patients with acute exacerbations of chronic bronchitis, the use of antibiotics is recommended; patients with severe exacerbations and those with more severe airflow obstruction at baseline are the most likely to benefit. Level of evidence, fair; net benefit, substantial; grade of recommendation, A 8. In stable patients with chronic bronchitis, the clinical benefits of postural drainage and chest percussion have not been proven, and they are not recommended. Level of evidence, fair; net benefit, conflicting; grade of recommendation, I
9. In patients with an acute exacerbation of chronic bronchitis, the clinical benefits of postural drainage and chest percussion have not been proven, and they are not recommended. Level of evidence, fair; net benefit, conflicting; grade of recommendation, I
10a. In stable patients with chronic bronchitis, therapy with short-acting ␤-agonists should be used to control bronchospasm and relieve dyspnea; in some patients, it may also reduce chronic cough. Level of evidence, good; net benefit, substantial; grade of recommendation, A 10b. In stable patients with chronic bronchitis, therapy with ipratropium bromide should be offered to improve cough. Level of evidence, fair; net benefit, substantial; grade of recommendation, A 10c. In stable patients with chronic bronchi-tis, treatment with theophylline should be considered to control chronic cough; careful monitoring for complications is necessary. Level of evidence, fair; net benefit, substantial; grade of recommendation, A 11. For patients with an acute exacerbation of chronic bronchitis, therapy with short-acting ␤-agonists or anticholinergic bronchodilators should be administered during the acute exacerbation. If the patient does not show a prompt response, the other agent should be added after the first is administered at the maximal dose. Level of evidence, good; net benefit, substantial; grade of recommendation, A 12. For patients with an acute exacerbation of chronic bronchitis, theophylline should not be used for treatment. Level of evidence, good; net benefit, none; grade of recommendation, D 13. For stable patients with chronic bronchitis, there is no evidence that the currently available expectorants are effective and therefore they should not be used. Level of evidence, low; net benefit, none; grade of recommendation, I
14. In stable patients with chronic bronchitis, treatment with a long-acting ␤-agonist when coupled with an ICS should be offered to control chronic cough. Level of evidence, good; net benefit, substantial; grade of recommendation, A 15. For stable patients with chronic bronchitis and an FEV 1 of < 50% predicted or for those patients with frequent exacerbations of chronic bronchitis, ICS therapy should be offered. Level of evidence, good; net benefit, substantial; grade of recommendation, A 16. For stable patients with chronic bronchitis, long-term maintenance therapy with oral corticosteroids such as prednisone should not be used; there is no evidence that it improves cough and sputum production, and the risks of serious side effects are high. Level of evidence, expert opinion; net benefit, negative; grade of recommendation, E/D 17. For patients with an acute exacerbation of chronic bronchitis, there is no evidence that the currently available expectorants are effective, and therefore they should not be used. Level of evidence, low; net benefit, none; grade of recommendation, I
18. For patients with an acute exacerbation of chronic bronchitis, a short course (10 to 15 days) of systemic corticosteroid therapy should be given; IV therapy in hospitalized patients and oral therapy for ambulatory patients have both proven to be effective. Level of evidence, good; net benefit, substantial; grade of recommendation, A 1. In patients with chronic cough who have normal chest radiograph findings, normal spirometry findings, and no evidence of variable airflow obstruction or airway hyperresponsiveness, the diagnosis of NAEB should be considered. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 2. In patients with chronic cough with normal chest radiograph findings, normal spirometry findings, and no evidence of variable airflow obstruction or airway hyperresponsiveness, the diagnosis of NAEB as the cause of the chronic cough is confirmed by the presence of airway eosinophilia, either by sputum induction or bronchial wash fluid obtained by bronchoscopy, and an improvement in the cough following corticosteroid therapy. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 3. In patients with chronic cough due to NAEB, the possibility of an occupation-related cause needs to be considered. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 4. For patients with chronic cough due to NAEB, the first-line treatment is ICSs (except when a causal allergen or sensitizer is identified [see recommendation 5]). Level of evidence, low; benefit, substantial; grade of recommendation, B 5. For patients with chronic cough due to NAEB, when a causal allergen or occupational sensitizer is identified, avoidance is the best treatment. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 6. For patients with chronic cough due to NAEB, if symptoms are persistently troublesome and/or the natural history of eosinophilic airway inflammation progresses despite treatment with high-dose ICSs, oral corticosteroids should be given. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A Chronic Cough Due to Bronchiectasis 17 1. In patients with suspected bronchiectasis without a characteristic chest radiograph finding, an high-resolution CT (HRCT) scan of the chest should be ordered because it is the diagnostic procedure of choice to confirm the diagnosis. Level of evidence, low; benefit, substantial; grade of recommendation, B 2. In patients for whom there is no obvious cause, a diagnostic evaluation for an underlying disorder causing bronchiectasis should be performed, because the results may lead to treatment that may slow or halt the progression of disease. Level of evidence, low; benefit, substantial; grade of recommendation, B 3. In patients with bronchiectasis with airflow obstruction and/or bronchial hyperreactivity, therapy with bronchodilators may be of benefit. Level of evidence, expert opinion; benefit, small; grade of recommendation, E/C 4. In patients with bronchiectasis caused by cystic fibrosis (CF), rhDNase should be used to improve spirometry. Level of evidence, low; benefit, small; grade of recommendation, C 5. In patients with CF, prolonged treatment with systemic corticosteroids should not be offered to most patients because of significant side effects. Level of evidence, low; benefit, conflicting; grade of recommendation, I
6. In patients with CF, prolonged courses of ibuprofen should not be used. Level of evidence, low; benefit, conflicting; grade of recommendation, I
7. In patients with idiopathic bronchiectasis, the prolonged systemic administration of antibiotics may produce small benefits in reducing sputum volume and purulence, but may also be associated with intolerable side effects. Level of evidence, low; benefit, conflicting, grade of recommendation, I
8. In patients with CF, therapy with aerosolized antipseudomonal antibiotics are recommended. Level of evidence, low; benefit, intermediate; grade of recommendation, C 9. In patients with idiopathic bronchiectasis, aerosolized antibiotics should not be used. Level of evidence, low; benefit, negative; recommendation, D 10. In patients with conditions associated with the hypersecretion of mucus and the inability to expectorate effectively, chest physiotherapy should be used and patients should be monitored for symptom improvement. Level of evidence, expert opinion; benefit, small/weak; grade of recommendation, E/C 11. In selected patients with localized bronchiectasis that causes intolerable symptoms despite maximal medical therapy, surgery should be offered. Level of evidence, low; benefit, substantial; grade of recommendation, B
12. In patients with exacerbations of bronchiectasis, antibiotics should be used, with the selection of agents depending on the likely pathogens. Level of evidence, low; benefit, substantial; grade of recommendation, B
Chronic Cough Due to Nonbronchiectatic
Suppurative Airway Disease (Bronchiolitis) 18 1. In patients with cough and incomplete or irreversible airflow limitation, direct or indirect signs of small airways disease seen on HRCT scan, or purulent secretions seen on bronchoscopy, nonbronchiectatic suppurative airways disease (bronchiolitis) should be suspected as the primary cause. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 2. In patients with cough in whom more common causes have been excluded, because bacterial suppurative airways disease may be present and clinically unsuspected, bronchoscopy is required before excluding it as a cause. Level of evidence, low; benefit, substantial; grade of recommendation, B 3. In patients in whom bronchiolitis is suspected, a surgical lung biopsy should be performed when the combination of the clinical syndrome, physiology, and HRCT findings do not provide a confident diagnosis. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 4. In patients with bacterial bronchiolitis, prolonged antibiotic therapy improves cough and is recommended. Level of evidence, low; benefit, substantial; grade of recommendation, B 5. In patients with toxic/antigenic exposure or drug-related bronchiolitis, cessation of the exposure or medication plus corticosteroid therapy for those with physiologic impairment is appropriate. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 6. In the inflammatory bowel disease (IBD) patient with cough, bronchiolitis should be suspected as a potential cause. Level of evidence, low; benefit, substantial; grade of recommendation, B 7. In patients in whom IBD-related bronchiolitis is suspected, both adverse drug reaction and infection should be specifically considered. an epidemiologic linkage to a confirmed case. Level of evidence, low; net benefit, substantial; grade of evidence, B 9. Children and adult patients with confirmed or probable whooping cough should receive a macrolide antibiotic and should be isolated for 5 days from the start of treatment because early treatment within the first few weeks will diminish the coughing paroxysms and prevent spread of the disease; treatment beyond this period may be offered but it is unlikely the patient will respond. Level of evidence, good; net benefit, substantial; grade of evidence, A 10. Long-acting ␤-agonists, antihistamines, corticosteroids, and pertussis Ig should not be offered to patients with whooping cough because there is no evidence that they benefit these patients. Level of evidence, good; net benefit, none; grade of evidence, D 1. In patients presenting with chronic cough, in order to determine that the angiotensinconverting enzyme (ACE) inhibitor is the cause of the cough, therapy with ACE inhibitors should be discontinued regardless of the temporal relation between the onset of cough and the initiation of ACE inhibitor therapy. The diagnosis is confirmed by the resolution of cough, usually within 1 to 4 weeks of the cessation of the offending agent; however, the resolution of cough may be delayed in a subgroup of patients for up to 3 months. Quality of evidence, low; net benefit, substantial; grade of recommendation, B 2. In patients presenting with chronic ACE inhibitor-induced cough, discontinue therapy with the drug because it is the only uniformly effective treatment. Quality of evidence, low; net benefit, substantial; grade of recommendation, B 3. In patients whose cough resolves after the cessation of therapy with ACE inhibitors, and for whom there is a compelling reason to treat with these agents, a repeat trial of ACE inhibitor therapy may be attempted. Quality of evidence, fair; net benefit, substantial; grade of recommendation, A 4. In patients for whom the cessation of ACE inhibitor therapy is not an option, pharmacologic therapy, including that with sodium cromoglycate, theophylline, sulindac, indomethacin, amlodipine, nifedipine, ferrous sulfate, and picotamide that is aimed at suppressing cough should be attempted. Quality of evidence, fair; net benefit, intermediate; grade of recommendation, B and are associated with significant side effects, an individualized analysis of the overall benefit and risk is necessary. Level 1. In patients with chronic cough, uncommon causes should be considered when cough persists after evaluation for common causes and when the diagnostic evaluation suggests that an uncommon cause, pulmonary as well as extrapulmonary (see Table 1 in section 28), may be contributing. Level of evidence, low; benefit, substantial; grade of recommendation, B 2. In patients with chronic cough, until uncommon causes that potentially may be contributing to the patient's cough have been ruled out, the diagnosis of unexplained cough should not be made. Level of evidence, low; benefit, substantial; grade of recommendation, B 3. If cough persists after consideration of the most common causes, perform a chest CT scan and, if necessary, a bronchoscopic evaluation. Level of evidence, low; benefit, substantial; grade of recommendation, B 4. In patients who present with abrupt onset of cough, consider the possibility of an airway foreign body. Level of evidence, low; benefit, substantial; grade of recommendation, B 5. In patients with unexplained cough, evaluate the possibility of drug-induced cough. Level of evidence, low; benefit, substantial; grade of recommendation, B 6. In patients with unexplained cough, consider a therapeutic trial of withdrawing the drug that is suspected to cause the cough. Level of evidence, low; benefit, substantial; grade of recommendation, B 1. In patients with cough, the starting point is the medical history and physical examination. Although the timing and characteristics of the cough are of little diagnostic value, the medical history is important to determine whether the patient is receiving an ACE inhibitor, is a smoker, or has evidence of a serious life-threatening or systemic disease. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 2. In patients with an acute cough, first determine whether the acute cough is a reflection of a serious illness such as pneumonia or pulmonary embolism, or, as is usually the case, a manifestation of a non-life-threatening disease such as a respiratory tract infection (eg, common cold or lower respiratory tract infection), an exacerbation of a preexisting condition (eg, COPD, UACS, asthma, or bronchiectasis), or an environmental or occupational exposure to some noxious or irritating agent (eg, allergic or irritant-induced rhinitis). Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 3. In patients with a subacute cough, first determine whether it is a postinfectious cough or not. If it is postinfectious, determine whether it is a result of UACS, transient bronchial hyperresponsiveness, asthma, pertussis, or an acute exacerbation of chronic bronchitis. If it is noninfectious, manage the cough the same way as chronic cough. Level of evidence, expert opinion; benefit, substantial; grade of recommendation, E/A 4a. In patients with chronic cough, systematically direct empiric treatment at the most common causes of cough (ie, UACS, asthma, NAEB, and GERD). Level of evidence, low; benefit, substantial; grade of recommendation, B 4b. In patients with chronic cough, therapy should be given in sequential and additive steps sation of exposure advised or initiated. Level of evidence, low; benefit, substantial; grade of recommendation, B 12. Children should be managed according to the studies and guidelines for children ( 1. As suggested in the various sections of this guideline, further research should be conducted to elucidate the mechanisms of the production of cough in various diseases and conditions, the optimal methods of assessment, and treatment, specific to the suspected cause. Level of evidence, expert opinion; benefit, substantial; strength of recommendation, E/A 2. Research is particularly needed in areas such as the treatment of postinfectious cough, the characterization of psychogenic cough, the methods of assessment of cough, and pharmacotherapy. Level of evidence, expert opinion; benefit, substantial; strength of recommendation, E/A
